Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ValiRx PLC targets US institutions with new appointment

Burns McClellan has already carried out an institutional investor introductory project for ValiRx.
ValiRx PLC targets US institutions with new appointment
ValiRx wants more recognition in the US

ValiRx Plc (LON:VAL) has appointed a specialist investor relations firm to build its recognition among academic, clinical, and business leaders in the US. 

Burns McClellan has already carried out an institutional investor introductory project for ValiRx

Satu Vainikka, ValiRx’s chief executive, said its relationship with Burns McClellan was developing strongly and the company would benefit from enhanced engagement with US investors and other key partners in the US biotech sector.

ValiRx has one drug, VAL201 targeting prostate cancer, going through phase I/II trials, and has made an application to start a second for another cancer treatment, VAL401 that focuses on locally advanced or metastatic non-small cell lung cancer.

PhilW.jpg
Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile

ValiRx Plc Timeline

Big Picture
May 19 2016

Related Articles

inhaler.jpg
April 05 2016
If the market worked as perfectly as its more rabid advocates insist, we wouldn’t have attractive anomalies such as Synairgen..
blood_56ceb82789b61.jpg
February 25 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
World map made out of drugs
April 12 2016
The pharma services and drug development group has hit key milestones in the last year.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.